Maven Securities LTD Invests $7.47 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Maven Securities LTD purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the biotechnology company's stock, valued at approximately $7,466,000. Ascendis Pharma A/S makes up 0.1% of Maven Securities LTD's portfolio, making the stock its 21st largest position. Maven Securities LTD owned approximately 0.08% of Ascendis Pharma A/S as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in shares of Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after acquiring an additional 267,881 shares during the period. Avoro Capital Advisors LLC grew its stake in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after acquiring an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock valued at $766,523,000 after acquiring an additional 170,942 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock valued at $278,760,000 after buying an additional 155,971 shares during the period. Finally, Fred Alger Management LLC grew its stake in shares of Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company's stock valued at $41,879,000 after buying an additional 120,952 shares during the period.

Analyst Ratings Changes

Several research firms have recently weighed in on ASND. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Bank of America increased their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. StockNews.com raised shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Jefferies Financial Group increased their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Price Performance

Shares of ASND traded down $0.34 during midday trading on Wednesday, reaching $131.01. The stock had a trading volume of 363,777 shares, compared to its average volume of 451,170. Ascendis Pharma A/S has a 1-year low of $101.43 and a 1-year high of $161.00. The company's fifty day simple moving average is $131.37 and its two-hundred day simple moving average is $132.53. The company has a market cap of $7.94 billion, a price-to-earnings ratio of -16.26 and a beta of 0.67.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts' expectations of $94.74 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -7.45 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.